Evidence map›Paper›PMID 29413084›Full record

ArticleThe Lancet. Respiratory medicine2018

Idiopathic pulmonary fibrosis: idiopathic no more?

Victor J Thannickal, Athol Wells, Martin Kolb

Abstract readComment
PubMed Publisher
In one paragraph

Article in The Lancet. Respiratory medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. NADPH Oxidase Inhibition in Fibrotic Pathologies.Antioxidants & redox signaling · 2020
    Article
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Victor J ThannickalDivision of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA. Electronic address: vthannickal@uabmc.edu.
Athol WellsDepartments of Medicine and Pathology/Molecular Medicine, McMaster University, Firestone Institute for Respiratory Health, Hamilton, ON, Canada.
Martin KolbInterstitial Lung Disease Unit, Royal Brompton Hospital, Royal Brompton and Harefield NHS Foundation Trust, London, UK.

Funding

Therapeutic Targeting of the Myofibroblast in Fibrotic Lung DiseaseP01HL114470 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI THANNICKAL, VICTOR J. · 2013 to 2022
$17.8M
Sirtuins in Lung Aging and FibrosisI01BX003056 · VA · SOUTHEAST LOUISIANA VETERANS HEALTH CARE · PI THANNICKAL, VICTOR J. · 2016 to 2025
–
BLRD VA I01 BX003056NHLBI NIH HHS P01 HL114470
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Idiopathic Pulmonary FibrosisPulmonary FibrosisHumans

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.